Literature DB >> 9095576

Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion.

Y Nakagawa1.   

Abstract

Nephrocalcin (NC), an acidic glycoprotein with molecular weight 14,000, is present in urine and prevents kidney stone formation. Histoimmunochemical staining shows that NC is localized in the proximal tubles in kidneys. Isolated NC from mammalian urine, revealed at least 4 isoforms of NC (we call these isoforms NC-A, NC-B, NC-C, and NC-D in the order of elution) during DEAE cellulose column chromatography with a linear gradient of NaCl elution step. Non-stone forming people excrete more NC-A and NC-B isoforms in urine; however, more NC-C and NC-D isoforms were found in stone formers' urine. When the organic matrix was extracted from surgically removed calcium oxalate kidney stones, we found greater quantities of NC-C and NC-D isoforms than those of NC-A and NC-B isoforms. Amino acid compositions and carbohydrate contents of these 4 isoforms were similar with the exception of the gamma-carboxyglutamic acid (GLA) residues. Only the NC-A and NC-B isoforms contained residues of GLA. There were more phosphate residues present in NC-C and NC-D than in NC-A and NC-B. Upon removal of phosphate residues by alkaline phosphatase, NC-C eluted at the same salt concentrations as NC-A eluted. This indicates that the backbone protein could be similar, but the NC-C isoform is modified by excess phosphate residues. Surface tension measurements using a Lauda film balance indicated that NC-A and -B were strongly amphiphilic while NC-C and -D were less amphiphilic. NC-A has an elongated shape, and occupies a smaller area per molecule; whereas NC-C is a bulky molecule. Using NC-A as a model of a "good" inhibitor and NC-C as a model of a "poor" inhibitor, both bound with 4 atoms of Ca2+ per molecule as investigated by equilibrium dialysis method, 31P-NMR, and electron spin resonance spectrometry. Isoforms A and B changed their conformation upon Ca2+ binding, but C and D did not change their conformation. All these observations suggest that isoforms A and B are strong inhibitors of calcium oxalate monohydrate (COM) crystal growth and aggregation. However, isoforms C and D act as promotors for COM crystal growth-kidney stone formation. Measuring the amount of NC in urine from renal cell carcinoma patients and from NC isolated from a supernatant of a primary renal cell carcinoma cells demonstrated the amount of NC increased with disease progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9095576     DOI: 10.2302/kjm.46.1

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  5 in total

1.  Comparison of cat and human calcium oxalate monohydrate kidney stone matrix proteomes.

Authors:  Jeffrey A Wesson; Roman Zenka; Jody Lulich; Jessica Eisenhauer; Carley Davis
Journal:  Urolithiasis       Date:  2022-09-30       Impact factor: 2.861

2.  Alteration of urinary macromolecules by adsorption on surfaces, probably an important factor in urolithiasis.

Authors:  J M Baumann; B Affolter; U von Arx; M Noël
Journal:  Urolithiasis       Date:  2013-09-14       Impact factor: 3.436

Review 3.  Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators.

Authors:  Kanu Priya Aggarwal; Shifa Narula; Monica Kakkar; Chanderdeep Tandon
Journal:  Biomed Res Int       Date:  2013-09-14       Impact factor: 3.411

4.  Stabilization of Calcium Oxalate Precursors during the Pre- and Post-Nucleation Stages with Poly(acrylic acid).

Authors:  Felipe Díaz-Soler; Carlos Rodriguez-Navarro; Encarnación Ruiz-Agudo; Andrónico Neira-Carrillo
Journal:  Nanomaterials (Basel)       Date:  2021-01-18       Impact factor: 5.076

Review 5.  Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity.

Authors:  Přemysl Mladěnka; Kateřina Macáková; Lenka Kujovská Krčmová; Lenka Javorská; Kristýna Mrštná; Alejandro Carazo; Michele Protti; Fernando Remião; Lucie Nováková
Journal:  Nutr Rev       Date:  2022-03-10       Impact factor: 7.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.